Genentech and Breastcancer.org Say It's "About Damn Time" We Talk About What Happens When Initial Breast Cancer Treatment Ends
Genentech Presents New Data at EURETINA, Highlighting Vabysmo's Real-World Effectiveness and Safety Across Major Retinal Conditions
Genentech's Giredestrant Combination Significantly Improved Progression-Free Survival in ER-positive Advanced Breast Cancer in Phase III evERA Data Published in The New England Journal of Medicine
Genentech's Fenebrutinib Is the First BTK Inhibitor to Receive U.S. FDA Filing Acceptance in Both Relapsing and Primary Progressive Multiple Sclerosis
Positive Interim Data Shows Genentech's Sefaxersen Significantly Reduces Proteinuria in People With IgA Nephropathy
Genentech Announces Positive Phase II Results for Dual GLP-1/GIP Receptor Agonist Enicepatide in People Living With Type 2 Diabetes and Overweight or Obesity
Genentech's Lunsumio-Based Regimen Significantly Improves Progression-Free Survival in Follicular Lymphoma in Phase III CELESTIMO Study
U.S. FDA Grants Priority Review for Genentech's Enspryng for MOGAD, an Autoimmune Disease With No Approved Treatments
Roche receives FDA approval for companion diagnostic tests to identify patients with HER2-positive metastatic gastroesophageal adenocarcinoma eligible for ZIIHERA
Roche receives FDA clearance for Elecsys® pTau217, advancing Alzheimer's disease assessment across primary and specialty care
Goldera Expands High-Grade E1 Gold Discovery with Two New Parallel Structures Ahead of Planned Q4 Drilling at Egan Gold Project
Oreterra CEO Letter to Shareholders Provides Forward Guidance on Trek South Drill Results in Advance of Assays
Renforth Intersects Broad Nickel-Cobalt and Zinc-Copper-Silver Mineralization in Victoria Undercut Drilling, Including 118.0 M of 0.081% Ni and 10.9 M of 0.544% Zn
